

Myriocin prevents fumonisin B₁-induced sphingoid base accumulation in mice liver without ameliorating hepatotoxicity

Quanren He^a, Ronald T. Riley^b, Raghubir P. Sharma^{a,*}

^a Department of Physiology and Pharmacology, College of Veterinary Medicine, The University of Georgia, Athens, GA 30602-7389, United States

^b Toxicology and Mycotoxin Research Unit, USDA-ARS, Athens, Georgia 30604, United States

Received 24 August 2004; accepted 30 January 2005

Abstract

Fumonisin B₁ (FB₁), a mycotoxin produced by *Fusarium verticillioides* present on corn and corn-based products, causes species- and organ-specific diseases. The hepatotoxic effects of FB₁ in mice have been closely correlated with the accumulation of free sphinganine, a marker for ceramide synthase inhibition, and reduced biosynthesis of more complex sphingolipids. It has been shown that FB₁ modulates expression of many cell signaling factors. In the current study we used myriocin, a specific inhibitor of serine palmitoyltransferase, to investigate the role of free sphinganine accumulation in FB₁-induced hepatotoxicity and increased expression of selected signaling genes in BALB/c mice. The mice were pretreated daily with intraperitoneal injection of 1.0 mg/kg myriocin 30 min before subcutaneous injections of 2.25 mg/kg of FB₁ for 3 days. Results showed that myriocin alone was not hepatotoxic and the combination of myriocin plus FB₁ completely prevented the FB₁-induced elevation of hepatic free sphinganine and prevented the FB₁-induced induction of selected cell signaling genes, suggesting that accumulation of free sphinganine and/or its metabolites contribute to the FB₁-modulation of the cell signaling factors. However, the combination of myriocin and FB₁ did not prevent FB₁-increased concentration of plasma alanine aminotransferase and only slightly attenuated aspartate aminotransferase; it did not affect the FB₁-induced hepatocyte apoptosis or increased cell proliferation. A longer combined treatment of myriocin and FB₁ was highly toxic. The hepatotoxic effects in mice seen in this study are most likely due to a combination of factors including accumulation of free sphinganine, depletion of more complex sphingolipids and sphingomyelin, or other unknown mechanisms.

© 2005 Elsevier Ltd. All rights reserved.

Keywords: Fumonisin; Myriocin; Cytokine expression; Hepatotoxicity; Sphinganine; Sphingolipids

1. Introduction

Fumonisin B₁ (FB₁) was first isolated in 1988 from the fungus *Fusarium verticillioides*, a common endophytic fungus in corn (Gelderblom et al., 1988). Several types of fumonisins have been identified so far as products of *F. verticillioides* in naturally contaminated corn and corn-based products. Fumonisin B₁ (FB₁) is the most abundant and most toxic of all fumonisin isomers inves-

tigated so far (WHO, 2000). Fumonisin B₁ induces species-specific toxicity. In horses this toxin is known to cause leukoencephalomalacia (Marasas, 2001); in pigs pulmonary edema and cardiovascular damage (Haschek et al., 2001; Smith et al., 1999). The high incidence of esophageal cancer in people in some areas of South Africa and China was correlated with *F. verticillioides* infection and fumonisin levels in corn (Marasas, 2001; Yoshizawa et al., 1994). It has been demonstrated that FB₁ is hepato- and nephro-carcinogenic in male rats (Gelderblom et al., 1991; Howard et al., 2001), and hepatocarcinogenic in female mice (Howard et al., 2001). Fumonisin B₁ is hepatotoxic and nephrotoxic in

* Corresponding author. Tel.: +1 706 542 2788; fax: +1 706 542 3015.
E-mail address: rpsharma@vet.uga.edu (R.P. Sharma).

rodents (Sharma et al., 1997; Voss et al., 1998, 2001). The cellular effects of fumonisins consist of a mixture of apoptosis and necrosis and regenerative proliferation (Lemmer et al., 1999; Howard et al., 2001; Sharma et al., 1997).

Fumonisin B₁ is structurally similar to free sphingoid bases (sphinganine and sphingosine), and inhibit ceramide synthase (sphingosine *N*-acyltransferase), a critical enzyme in the pathway of de novo sphingolipid synthesis (Merrill et al., 2001; Wang et al., 1991). By inhibiting ceramide synthase, FB₁ increases the level of free sphinganine in tissues, serum, and urine (Riley et al., 1993, 1996, 1997; Wang et al., 1992, 1999), decreases complex sphingolipids (Wang et al., 1992; Yoo et al., 1996), and increases the formation of other lipid metabolites such as sphingoid base-1-phosphates and their downstream metabolites (Merrill et al., 2001; Smith and Merrill, 1995). The hepatotoxicity of FB₁ is closely correlated with the accumulation of free sphinganine in male BALB/c (Tsunoda et al., 1998) and other mouse strains (Riley et al., 2001).

Serine palmitoyltransferase (SPT), the first enzyme in the pathway for de novo biosynthesis of sphingolipids, catalytically incorporates L-serine into palmitoyl-coenzyme A to produce 3-keto-sphinganine, the immediate precursor of sphinganine (Hannun et al., 2001, Fig. 1). Inhibition of SPT to reduce free sphinganine accumulation reversed FB₁ toxicity in mammalian cell cultures (He et al., 2002a; Riley et al., 1999a,b; Schmelz et al.,

1998; Tolleson et al., 1999; Yoo et al., 1996). Myriocin, a selective inhibitor of SPT (Miyake et al., 1995), prevented accumulation of free sphinganine in kidney of mice exposed to FB₁, and therefore it was proposed that myriocin might be useful in protecting against FB₁ toxicity in vivo (He et al., 2002a; Riley et al., 1999a).

Numerous studies have shown that FB₁ modulates the expression of inflammatory cytokines and other cell signaling factors. For example, FB₁ treatment induced the expression of tumor necrosis factor (TNF) and pro-apoptotic signaling genes in liver and kidney of mice (Bhandari and Sharma, 2002; Bhandari et al., 2002). Peritoneal macrophages from FB₁-treated mice produced higher amount of TNF α than those from saline controls in response to lipopolysaccharide ex vivo (Dugyala et al., 1998). Treatment of LLC-PK₁ cells, a pig renal epithelial cell line, with FB₁ transiently increased the expression of TNF α but this induction of TNF α by FB₁ was unaltered when free sphinganine accumulation was prevented in the cultures by myriocin (He et al., 2001). Expression of TNF α receptor-associated protein (TRAP) 2 was induced in FB₁-sensitive CV-1 cells but repressed in FB₁-resistant COS cells (Zhang et al., 2001). It remains uncertain whether FB₁-induced alterations of gene expression in tissues are due solely to the disruption of sphingolipid metabolism.

Myriocin is able to inhibit the activity of hepatic SPT in mice (He et al., 2004a), and subsequently prevent the accumulation of free sphinganine in response to FB₁ both in vivo and in vitro (Enongene et al., 2002; Riley et al., 1999a; Schmelz et al., 1998). It has been widely used to study the role of sphinganine and de novo generated ceramide in regulation of cell functions under various conditions (He et al., 2001, 2002a,b; Le Stunff et al., 2002; Riley et al., 1999a; Schmelz et al., 1998). In the present study, we investigated the effect of myriocin on FB₁ hepatotoxicity and gene expression of selected cytokines in mice. Myriocin effectively blocked the activity of SPT and prevented the FB₁-accumulation of free sphinganine in both liver and kidney; however, it did not reduce FB₁-induced hepatocyte apoptosis or increased proliferating cell nuclear antigen (PCNA) containing cells. The FB₁-induced plasma alanine aminotransferase (ALT) was unaltered by myriocin pretreatment; the elevation of plasma aspartate aminotransferase (AST) was significantly reduced. In spite of minimal protection against FB₁-induced hepatotoxicity, myriocin reversed the FB₁-induced increases in the expression of TNF α ; TNF related apoptosis-inducing ligand (TRAIL), TNF α receptor (TNFR)1, lymphotxin (LT) β , Interferon (IFN) γ , and transforming growth factor (TGF) β 1. Results suggested that elevation in free sphinganine and/or its metabolites are involved in FB₁-induced alterations in expression of various cell signaling factors. However, with the dosing regime used in




Fig. 1. (a) Sphingolipid pathways indicating inhibition of serine palmitoyltransferase by myriocin and ceramide synthase by fumonisin B₁. Treatment of animals with myriocin decreases synthesis of all sphingolipids, whereas treatment with FB₁ results in the increase of sphinganine, sphingosine and their respective phosphates along with decrease in ceramide and complex sphingolipids. (b) Structural similarity of myriocin and fumonisin B₁ with free sphingoid base sphingosine.

Download English Version:

<https://daneshyari.com/en/article/9031032>

Download Persian Version:

<https://daneshyari.com/article/9031032>

[Daneshyari.com](https://daneshyari.com)